Splenic marginal zone lymphoma

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
4 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 3
Mechanism of action (INN-stem analysis)
Monoclonal antibody (tumor, humanized) 1 substance
Unknown / small molecule 1 substance
Monoclonal antibody (chimeric) 1 substance
BTK inhibitor 1 substance
Phase III: 1 Phase II: 2 Phase I: 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • Association International Extranodal Lymphoma Study Group (IELSG) Academic
    RITUXIMAB; ZANUBRUTINIB
    2023-503755-10-00 7 countries 2024 n=90
    Ended

Phase II

2 trials
  • Universitaetsklinikum Ulm AöR Academic
    OBINUTUZUMAB
    2024-517476-38-00 1 country 2018 n=56
    Ended
  • University Hospital Of Ulm AöR Academic
    COPANLISIB DIHYDROCHLORIDE; RITUXIMAB
    2022-500674-34-00 1 country 2019 n=36
    Ended

Phase I

1 trial
  • Nurix Therapeutics Inc. Commercial
    IMP not specified
    2023-510541-25-00 5 countries 2023 n=250
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Nurix Therapeutics Inc. Commercial 1 Phase I 1
Universitaetsklinikum Ulm AöR Academic 1 Phase II 0
University Hospital Of Ulm AöR Academic 1 Phase II 0
Association International Extranodal Lymphoma Study Group (IELSG) Academic 1 Phase III 0
New trials by year
2019
1
2023
1
2024
1
← All indication landscapes